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Abstract Rapamycin is a potent immunosuppressant with
antitumoral properties widely used in the field of renal
transplantation. To test the hypothesis that the antiprolifer-
ative and antiangiogenic activity of rapamycin interferes
with the normal structure and function of growth plate and
impairs longitudinal growth, 4-week-old male rats (n=10/
group) receiving 2 mg/kg per day of intraperitoneal
rapamycin (RAPA) or vehicle (C) for 14 days were
compared. Rapamycin markedly decreased bone longitudi-
nal growth rate (94±3 vs. 182±3 μm/day), body weight
gain (60.2±1.4 vs. 113.6±1.9 g), food intake (227.8±2.6
vs. 287.5±3.4 g), and food efficiency (0.26±0.00 vs. 0.40±
0.01 g/g). Signs of altered cartilage formation such as
reduced chondrocyte proliferation (bromodeoxiuridine-la-
beled cells 32.9±1.4 vs. 45.2±1.1%), disturbed maturation
and hypertrophy (height of terminal chondrocytes 26±0 vs.
29±0 μm), and decreased cartilage resorption (18.7±0.5 vs.
31.0±0.8 tartrate-resistant phosphatase alkaline reactive
cells per 100 terminal chondrocytes), together with mor-
phological evidence of altered vascular invasion, were seen
in the growth plate of RAPA animals. This study indicates
that rapamycin can severely impair body growth in fast-
growing rats and distort growth-plate structure and dynam-
ics. These undesirable effects must be kept in mind when
rapamycin is administered to children.
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Introduction
Rapamycin has raised great interest in the field of renal
transplantation in recent years. Early studies were per-
formed in adults in which rapamycin was used as a rescue
agent for acute and chronic graft rejection as well as for
primary immunosuppression [1]. Rapamycin-based regi-
mens have been reported to provide effective rejection
prophylaxis without the risks of hypertension and decline in
renal function associated with calcineurin inhibitors [2].
Most interestingly, rapamycin treatment in combination
with other immunosuppressants has been reported to
improve renal function [3, 4] and to decrease the elevated
risk of developing cancer in renal transplanted patients [5].
At present, there is very little information on the use of
rapamycin in pediatric solid organ transplantation [1, 6, 7].
The effects of rapamycin on longitudinal growth have not
been assessed in pediatric clinic trials. Rapamycin has been
reported to reduce cellular proliferation in several in vitro
models [8] and to inhibit vascular endothelial growth factor
(VEGF) synthesis in animals [9]. Chondrocyte proliferation
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and vascular invasion of the epiphyseal growth plate are two
milestones of the endochondral ossification process. There-
fore, rapamycin has the potential to alter growth-plate func-
tion and impair longitudinal bone growth. In animal studies,
rapamycin administration has been shown to reduce weight
gain [10, 11]. In addition, decreased longitudinal growth rate
has been reported in adult rats given rapamycin [12].
Based on the above rationale, the study presented here
explored the hypothesis that rapamycin treatment might
adversely influence growth, and growth-plate structure and
dynamics of fast-growing young individuals.
Animals and methods
Male Sprague-Dawley rats aged 4 weeks and weighing 70±
5 g were housed in individual cages under controlled
conditions of light (12 h light/dark cycle) and temperature
(21–23°C). All animals received standard rat chow (A03,
Panlab, Barcelona, Spain) and tap water ad libitum. The
study complied with current legislation on animal experi-
ments in the European Union and was approved by the
Ethical Committee on Animal Research of our institution.
Experimental protocol and sample collection
After 4 days of acclimation, animals were classified in two
groups of ten individuals each: control (C) and rapamycin-
treated (RAPA) rats. From day 0 to day 13 of the protocol,
2 mg/kg per day of rapamycin, purchased from LC Labs (LC
Laboratories, Woburn, MA, USA), were administered intra-
peritoneally at 10 A.M. to the RAPA group. C animals
received intraperitoneal injections of vehicle (5% dimethyl-
sulfoxide; DMSO; Sigma, St. Louis, MO, USA). Animals
were sacrificed under anesthesia on day 14 of the protocol
approximately at the time of daily rapamycin injection. Three
days before sacrifice, each animal received 30 mg/kg of
calcein (Sigma, St. Louis, MO, USA) by intraperitoneal route.
Bromodeoxyuridine (BrdU; 100 mg/kg; Sigma) was injected
intraperitoneally 1, 9 and 17 h before death. At sacrifice,
blood samples were collected and stored at −20C° until mea-
surement of rapamycin concentrations. Tibiae were removed
and the proximal ends fixed and processed for methyl meth-
acrylate embedding, as previously described [13]. Right tibiae
were fixed in 40% ethanol for analysis of calcein labeling and
BrdU immunohistochemistry. Left tibiae were fixed in 4%
neutral formalin at 4°C and used for other morphometric,
cytochemical, and immunocytochemical studies.
Rapamycin blood concentration
Trough concentrations of rapamycin were measured in
whole blood using an Abbott IMx analyzer using the IMx
sirolimus MEIA kit (Abbott Laboratories, Abbott Park, IL,
USA) following manufacturer’s instructions.
Growth and nutrition
Food intake and body weight were measured daily using an
electronic balance (Ohaus GT 2100, Florham Park, NJ,
USA). Nose to tail-tip length was measured under anesthesia
on day 14. Food efficiency was calculated as the ratio be-
tween weight gained and food consumed (g/g) by each
animal between days 0 and 13 of the protocol. Longitudinal
growth rate was measured in 10-μm-thick frontal sections of
the proximal end of tibiae obtained using a rotary microtome
(HM355S, Microm, Barcelona, Spain) fitted with tungsten
carbide blades. Sections were examined under an Olympus
incident light fluorescence microscope (Olympus BX41,
Olympus Optical España, Barcelona, Spain) coupled to a
digital camera (Olympus DP11, Olympus Optical España,
Barcelona, Spain) to detect calcein label. Images were captured
and the distance between the chondro-osseous junction, and
the calcein label was measured using an image analysis system
(Scion Image, Scion Corporation, Frederick, MD, USA). The
average value of these measurements divided by three was
considered as the daily longitudinal bone growth during the
last 3 days of either rapamycin or vehicle administration.
Histology and histomorphometry
Frontal sections (5-μm thick) of proximal tibiae fixed in
formalin were stained by the following methods: alcian
blue/safranine for morphometric analysis, Von Kossa stain-
ing for mineralization analysis, tartrate-resistant acid phos-
phatase (TRAP) stain for osteoclast identification, periodic
acid-Schiff (PAS) reaction to stain glycogen deposits, and
picrosirius red/alcian blue/hematoxylin for analysis of bone
and cartilage extracellular matrix. Heights of growth
cartilage and its hypertrophic zone were identified following
morphologic criteria and measured at regular intervals using
an image analysis system described elsewhere [13]. Height
of the three most distal hypertrophic chondrocytes was
measured in alternate columns using the same system. The
number of TRAP-positive cells at the vascular invasion
front was measured in an area extending 50 μm from the
distal end of growth cartilage into the primary spongiosa in
two slides per animal. The results were expressed as the
number of positive cells per 100 terminal chondrocytes.
Immunohistochemical analysis of proliferating
chondrocytes
Immunodetection of BrdU-labeled cells was carried out as
previously described [13]. Briefly, after deplastination and
rehydration, frontal 5-μm-thick sections were rinsed in
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0.1 M Tris-hydrochloric buffer and treated with trypsin
(1 mg/ml, 0.1% CaCl2; 60 min, 37°C). Endogenous
peroxidase activity was inactivated by 30-min treatment in
3% hydrogen peroxide, and horse serum (1:5, 75 min;
Sigma, St. Louis, MO, USA) was used to block unspecific
reactions. Then, samples were incubated for 48 h (4°C in a
moist chamber) with monoclonal antibody to BrdU (1:20;
Dako Diagnosticos SA, Barcelona, Spain) followed by
reaction with anti-mouse secondary conjugated antibody
(EnVision, Dako Diagnosticos SA). The final reaction
product was revealed with diaminobenzidine, and sections
were lightly counterstained with alcian blue. Two sections
were analyzed per animal, and the proliferating activity was
expressed as the number of positive cells per 100 cells in the
proliferative zone, defined for this purpose as the band of
tissue comprised between the resting zone and a line traced
by the most distal BrdU-labeled cells.
Immunohistochemical analysis for VEGF
VEGF immunohistochemical staining was performed in
5-μm-thick sections of the proximal end of tibiae fixed in
formalin. After deplastination in acetone and rehydration,
all sections were treated with hydrogen peroxide and goat
serum as described above. Then, sections were incubated
overnight at 4°C with a 6/100 solution of polyclonal anti-
VEGF antibody (Neo Markers, Westinghouse, CA, USA).
After 30 min incubation with anti-rabbit secondary
conjugated antibody (EnVision; Dako Diagnosticos), the
final reaction product was revealed with diaminobenzi-
dine and methyl green was used as counterstaining.
Statistical analysis
Values are given as mean ± standard error of the mean
(SEM). Comparisons among groups were carried out by
Student’s t test. A P value ≤0.05 was considered significant.
All data sets were analyzed using SPSS 11.0 software
package (SPSS Inc., Chicago, IL, USA).
Results
Rapamycin trough blood levels in the RAPA group were
22.3±2.1 ng/ml. As shown in Table 1, these animals
exhibited marked growth impairment, as demonstrated by
reductions in weight gain, nose to tail-tip length, and
longitudinal bone growth rate when compared with control
animals. Significant decreases in food intake and food
efficiency were also observed in RAPA animals when
compared with C animals. Representative images of tibial
growth-plate sections illustrating the differences in longitu-
dinal bone growth rate are shown in Fig. 1.
Histology and histomorphometry of the growth cartilage
Heights of both the growth cartilage and its hypertrophic
zone greatly varied in RAPA animals, sometimes being
greater than in C animals (Fig. 2a,b). The histomorpho-
metric analysis did not demonstrate significant differences
in either the height of epiphyseal cartilage (C: 493±32 μm;
RAPA: 629±47 μm) or the height of the hypertrophic zone
(C: 347±28 μm; RAPA: 437±38 μm).
Even in a context of evident morphological variability,
some histological features were consistently present in most
samples from RAPA animals (Fig. 2b–e). The proliferative
zone was frequently disorganized, with loss of the normal
columnar pattern. Acellular regions of fibrinous material
markedly stained with alcian blue were often found in this
zone (Fig. 2c). The transition between proliferative and
hypertrophic zones was sometimes ill defined; others were
quite abrupt (Fig. 2b–c). Groups of flattened hypertrophic
chondrocytes, with their long axis oriented perpendicular to
the longitudinal axis of the bone, were found near the distal
end of cartilage (Fig. 2d). Morphometric analysis revealed
that the mean height of terminal chondrocytes was
significantly lower in RAPA (26±0 μm) than in C animals
(29±0 μm). The chondro-osseous junction in RAPA
samples was not as neat and regular as in C animals, with
zones distorted by clusters of hypertrophic chondrocytes
extending into the depth of the primary spongiosa (Fig. 2e).
Isolated chondrocytes were occasionally seen within the
metaphyseal bone.
In C animals, PAS-positive cytoplasmic granules were
clearly seen in chondrocytes of the upper hypertrophic zone
(Fig. 3a), and marked cells were gradually disappearing
toward the vascular invasion front. In RAPA samples,
chondrocytes containing PAS-positive material were seen in
a wider area, including most of the hypertrophic zone, and
strongly stained chondrocytes were identifiable near the
distal end of the growth cartilage (Fig. 3b). Von-Kossa
staining (Fig. 4) revealed that mineralization of cartilage
Table 1 Growth and food intake data [mean ± standard error of the
mean (SEM)] of control rats (C) and rats treated with rapamycin
(RAPA)
C RAPA
Weight gain (g) 113.6±1.9 60.2±1.4*
Length (cm) 35.1±0.2 32.4±0.1*
Longitudinal growth rate (μm/day) 549±13 279±17*
Foot intake (g) 287.5±3.4 227.8±2.6*
Food efficiency (g/g) 0.40±0.01 0.26±0.00*
Food efficiency was calculated as grams of gained weight divided by
grams of consumed food
*P<0.05
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matrix in control animals (Fig. 4a) was mostly confined to
longitudinal septa flanked by the last two or three
chondrocytes of adjacent columns. In RAPA samples
(Fig. 4b), a wider band of mineralized cartilage matrix
was seen, mineralization affecting not only to longitudinal
septa but also to transversal septa. In this group, chon-
drocytes were often seen immersed in a mass of mineral-
ized matrix.
Fig. 1 Representative sections of proximal tibial growth plates of
control (C; a) and rapamycin-treated (RAPA; b) rats. The mean
distance between the metaphyseal end of the growth plate and the
fluorescent calcein front indicates longitudinal bone growth rate
during the last 3 days of the study. Magnification bars: 100 μm
Fig. 2 Representative sections of proximal tibial growth plates of
control (C; a) and rapamycin-treated (RAPA; b–e) animals stained with
alcian blue/safranine. Details of proliferative zone of RAPA proximal
tibial growth plates (c), hypertrophic zone of RAPA proximal tibial
growth plates (d), and metaphyseal front of RAPA proximal tibial
growth plates (e). Magnification bars: 100 μm
Fig. 3 Periodic acid-Schiff (PAS) reaction in the proximal tibial
growth plate of control (C; a) and rapamycin-treated (RAPA; b)
animals. Cytoplasmic glycogen deposits in control rats are shown at
greater augmentation. Magnification bars: 100 μm
Fig. 4 Von-Kossa staining showing matrix mineralization of proximal
tibial growth plates of control (C; a) and rapamycin-treated (RAPA; b)
animals. Magnification bars 100 μm
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Cellular proliferation in growth cartilage
BrdU-labeled nuclei were easily identified throughout the
proliferative zone in samples from both groups (Fig. 5). The
percentage of labeled nuclei in the proliferative zone was
significantly higher in C (45.2±1.1%) (Fig. 5a) than in
RAPA (32.9±1.4%) samples (Fig. 5b).
Vascular invasion front and primary spongiosa
Dispersed TRAP-positive elements (chondroclasts/osteo-
clasts) were found in septa of the primary spongiosa and
along the vascular invasion front in the two groups of rats
(Fig. 6). Direct examination under the microscope showed
that TRAP-positive elements at the chondro-osseous junc-
tion had a somewhat regular distribution in C animals
(Fig. 6a)—approximately one every three terminal chon-
drocytes. In the same area of RAPA samples (Fig. 6b),
fewer and irregularly distributed TRAP-reactive cells were
seen. The number of TRAP-reactive cells per 100 terminal
chondrocytes in RAPA samples (18.7±0.5) was less than
that of controls (31.0±0.8).
Picrosirius red/alcian blue staining highlighted mor-
phological and structural differences in the primary
spongiosa of both groups (Fig. 7). Thin longitudinal septa,
parallel to the long axis of bone, defined the primary
spongiosa in control animals (Fig. 7a). These longitudinal
trabeculae, built on a nucleus of cartilage matrix-blue–
covered by a thin layer of bone matrix-red (insert in
Fig. 7a)–marked the path of invading capillary sprouts.
The longitudinal arrangement of septa and vessels was
distorted in RAPA samples (Fig. 7b) by the presence of
transverse unresorbed septa made of cartilage and/or bone
matrix. As opposed to the slender structure of primary
trabeculae found in control animals, thicker trabeculae,
including empty rings of cartilage or bone matrix, were
often seen in the primary spongiosa of treated animals
(insert in Fig. 7b).
Fig. 5 Bromodeoxyuridine
(BrdU)-labeled nuclei in the
proximal tibial growth plate of
control (C; a) and rapamycin-
treated (RAPA; b) animals
counterstained with alcian blue.
Magnification bars: 100 μm
Fig. 6 Tartrate-resistant acid
phosphatase (TRAP) stain in
proximal tibial growth plates of
control (C; a) and rapamycin-
treated (RAPA; b) animals.
Magnification bars: 100 μm
Fig. 7 Picrosirius red/alcian
blue/hematoxylin staining of
proximal tibial growth plates of
control (C; a) and rapamycin-
treated (RAPA; b) animals with
details of the structure of the
primary trabeculae. Magnifica-
tion bars: 100 μm
Fig. 8 Vascular endothelial
growth factor (VEGF) immuno-
histochemical stain counter-
stained with methyl green in
proximal tibial growth plates of
control (C; a) and rapamycin-
treated (RAPA; b, c, d) animals.
Magnification bars: 100 μm
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Immunohistochemistry for VEGF
VEGF immunohistochemical signal was intracellular and
localized within the cytoplasm of hypertrophic chondro-
cytes in the control group (Fig. 8a). In RAPA animals, no
uniform pattern for VEGF immunostaining was seen
(Fig. 8b–d). In some cases, VEGF immunostaining was
indistinguishable from that seen in controls (Fig. 8b). In
other samples, VEGF signal was found irregularly dis-
persed in the hypertrophic zone, and terminal chondrocytes
were rarely immunopositive (Fig. 8c). In some sections,
both patterns coexisted in the same sample, particularly in
those samples with narrow and widened cartilage zones
(Fig. 8d). A regular staining of the hypertrophic zone was
generally found in nonexpanded areas of the growth
cartilage whereas scanty and dispersed labeled cells were
seen in areas of expanded hypertrophic zone.
Discussion
The study presented here shows that administration of
rapamycin to fast-growing rats impairs longitudinal growth
and induces marked alterations in growth-plate structure. In
agreement with previous studies in adult animals [10, 11,
14, 15], rapamycin treatment was followed by a significant
reduction of body-weight gain and food intake. Interesting-
ly, the lower food efficiency of animals given rapamycin
compared with that of controls clearly shows that reduction
of body-weight gain was not just caused by food intake
reduction but points to a direct negative effect of rapamycin
on weight gain. Oral gavage has been reported to
significantly decrease both food intake [16] and rapamycin
biodisponibility [17]. To avoid these adverse effects, we
injected the drug intraperitoneally, unlike former reports
[10, 15] in which rapamycin was given by oral gavage.
Although trough rapamycin levels in the treated animals of
our study were slightly above those previously reported to
induce immunosuppression in rats [10], no evidence of
toxicity was noted. Additional studies will be of interest to
identify the critical ages and doses at which rapamycin
inhibits normal growth.
The marked decrease of longitudinal growth rate in
rapamycin-treated young animals was a relevant finding of
this study. Romero et al. [12], in the only study to date
reporting the effect of rapamycin on longitudinal growth,
stated that the reduction of growth velocity (about 30%)
found in their experimental model in adult rats might be of
little importance in adults but would acquire special
relevance in young individuals. This is fully confirmed in
the present report. We found a longitudinal growth rate
reduction of approximately 50% in young animals treated
with rapamycin in comparison with control animals.
Further experiments including pair-fed animals will be
needed to clarify the role played by rapamycin-induced
food intake reduction in this remarkable fall of growth rate.
However, on the base of our experience with food
restriction in several experimental models using rats of
similar age, it can be pointed out that the severe growth
retardation found in the rats treated with rapamycin was not
mainly due to food intake reduction. We have previously
shown [18] that a 37% food intake restriction decreases
daily growth rate approximately 13%, whereas the 20%
food intake reduction of the RAPA group reduced growth
velocity to 50%. Further to this, the mild growth retardation
found in the above-mentioned food-restricted animals was
never accompanied by the pronounced alterations of
growth-plate morphology found in the rapamycin-treated
animals.
The effects of rapamycin on bone metabolism have been
addressed by several studies in recent years [12, 19, 20],
but its effects on the growth plate are analyzed here for the
first time. Taking together data from the growth cartilage
and the adjacent primary spongiosa, our study indicates that
both the production and degradation of epiphyseal cartilage
were adversely affected by rapamycin treatment.
As shown by the immunostaining of BrdU-labeled
nuclei, proliferation of growth-plate chondrocytes was
markedly diminished by rapamycin treatment. This, indeed,
contributed to a decline in the production of growth
cartilage. The reduction of the proliferative activity of
chondrocytes may likely be related to the antiproliferative
action of rapamycin. Mammalian target of rapamycin
(mTOR) has been described as a downstream effector of
insulin-like growth factor type I (IGF-I) in various
experimental studies [21–24]. Therefore, it can be hypoth-
esized that blockade of the IGF-I/mTOR metabolic route by
rapamycin would partly inhibit IGF-I stimulus of cellular
proliferation, hence decreasing chondrocyte proliferation
rate.
Several findings of our study, such as the disorganization
of both proliferative and maturative zones, the abnormal
presence of glycogen deposits in distal hypertrophic
chondrocytes, and the flattening of terminal hypertrophic
chondrocytes, support the notion that rapamycin altered the
normal process of maturation and hypertrophy of chondro-
cytes. The decreased height of terminal hypertrophic
chondrocytes may play an important role in the decreased
growth rate of the animals treated with rapamycin because
chondrocyte enlargement supports nearly 60% of longitu-
dinal bone growth in young rats [25], and height of terminal
chondrocytes and longitudinal growth rate have been
shown to be positively correlated [18].
Morphological distortion of the maturation zone and
presence of PAS-positive glycogen granules in distal
hypertrophic chondrocytes have been previously interpreted
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as a disruption of the orderly process of maturation of
chondrocytes in a model of parathyroid-hormone-related
peptide (PTHrP)-depleted mice [26]. Therefore, our results
encourage the further study of rapamycin interaction with
the Indian hedgehog (Ihh)/PTHrP feedback loop [27], so far
not explored.
The presence of acellular regions of fibrinous material in
the proliferative zone and the altered mineralization of
transverse septa might well stand for extracellular matrix
alterations. Beyond providing support for growth-plate
chondrocytes, the extracellular matrix is involved in the
control of growth factor diffusion [27] and is linked to
cartilage mineralization. The matrix structure varies in
transverse and longitudinal cartilage septa [28] and, worthy
of note, matrix mineralization does occur in longitudinal
septa of the lower hypertrophic zone, whereas transverse
septa are rarely mineralized [29]. Recent studies indicate
that perivascular cells degrade unmineralized matrix and
transverse septa, whereas osteoclasts are involved in
degradation of longitudinal septa and mineralized cartilage
[30]. Our data support that degradation of cartilage matrix
by both the action of osteoclasts and that of invading
capillary sprouts is compromised in rapamycin-treated
animals. On the one hand, rapamycin treatment yielded a
significant reduction in the number of TRAP-positive cells
at the metaphyseal front. This agrees with the decreased
number of osteoclasts and osteoclast activity recently
reported in adult rats receiving everolimus [31]. On the
other hand, the arrangement of capillary sprouts among
slender longitudinal septa in the primary spongiosa was
clearly distorted after rapamycin treatment, with many
vascular channels running parallel to the chondro-osseous
junction. This could be the result of certain matrix
refractoriness to resorption stimuli and/or the alteration of
the signaling pathways controlling vascular invasion.
Growth-plate vascularization is a key step required for
degradation of cartilage and bone formation [32, 33]. It is of
note that hypertrophic chondrocytes play a significant role
in the process of vascular invasion by producing angiogenic
factors, such as VEGF [33] or fibroblast growth factor
(FGF) [34], and angiostatic molecules, such as chondro-
modulin [35]. The premise that rapamycin inhibits VEGF
synthesis [9] led us to analyze the expression of VEGF by
growth-plate chondrocytes. As opposed to the rather
homogeneous VEGF immunostaining of the hypertrophic
zone both in control rats and in nonexpanded areas of
growth cartilage from treated animals, scanty and dispersed
labeled cells were seen in areas of widened hypertrophic
zone from RAPA samples. This is consistent with the
increased width of hypertrophic zone and suppression of
vascular invasion found after inactivation of VEGF in mice
[33] and supports a heterogeneous effect of rapamycin in
the growth plate, with somewhat focal alterations.
Removal of terminal chondrocytes by programmed cell
death is of undeniable relevance for the homeostasis of the
growth plate. However, conceptual and technical approaches
to quantify this phenomenon are really controversial [36,
37]. No attempt was made here to evaluate programmed cell
death, but the presence of well-preserved, isolated chon-
drocytes in the primary spongiosa of RAPA samples
strongly suggests that chondrocyte removal from the growth
cartilage was also impaired by rapamycin treatment.
In summary, our study shows that administration of
rapamycin to young, fast-growing individuals severely
impairs growth and the structure and dynamics of long-bone
growth plate. These findings open the way to further studies
aimed at exploring the pathogenic mechanisms of these effects
and warn about the extensive use of rapamycin in transplanted
children until studies analyzing the impact of rapamycin
treatment on growth in the clinical setting are accomplished.
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